The Potential Anticancer Activity of 5-Fluorouracil Loaded in Cellulose Fibers Isolated from Rice Straw.
Antimetabolites, Antineoplastic
/ administration & dosage
Cell Line
Cell Line, Tumor
Cellulose
/ chemistry
Colorectal Neoplasms
/ drug therapy
Drug Carriers
/ administration & dosage
Drug Liberation
Drug Stability
Fluorouracil
/ administration & dosage
HCT116 Cells
Humans
Nasopharyngeal Neoplasms
/ drug therapy
Oryza
/ chemistry
Spectrophotometry, Ultraviolet
Spectroscopy, Fourier Transform Infrared
Thermogravimetry
X-Ray Diffraction
5-fluorouracil
cancer treatment
cellulose fibers
cytotoxicity assays
drug delivery
rice straw
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
02
2020
accepted:
15
07
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Green-based materials have been increasingly studied to circumvent off-target cytotoxicity and other side-effects from conventional chemotherapy. Here, cellulose fibers (CF) were isolated from rice straw (RS) waste by using an eco-friendly alkali treatment. The CF network served as an anticancer drug carrier for 5-fluorouracil (5-FU). The physicochemical and thermal properties of CF, pure 5-FU drug, and the 5-FU-loaded CF (CF/5-FU) samples were evaluated. The samples were assessed for in vitro cytotoxicity assays using human colorectal cancer (HCT116) and normal (CCD112) cell lines, along with human nasopharyngeal cancer (HONE-1) and normal (NP 460) cell lines after 72-hours of treatment. XRD and FTIR revealed the successful alkali treatment of RS to isolate CF with high purity and crystallinity. Compared to RS, the alkali-treated CF showed an almost fourfold increase in surface area and zeta potential of up to -33.61 mV. SEM images illustrated the CF network with a rod-shaped structure and comprised of ordered aggregated cellulose. TGA results proved that the thermal stability of 5-FU increased within the drug carrier. Based on UV-spectroscopy measurements for 5-FU loading into CF, drug loading encapsulation efficiency was estimated to be 83 ±0.8%. The release media at pH 7.4 and pH 1.2 showed a maximum drug release of 79% and 46%, respectively, over 24 hours. In cytotoxicity assays, CF showed almost no damage, while pure 5-FU killed most of the both normal and cancer cells. Impressively, the drug-loaded sample of CF/5-FU at a 250 µg/mL concentration demonstrated a 58% inhibition against colorectal cancer cells, but only a 23% inhibition against normal colorectal cells. Further, a 62.50 µg/mL concentration of CF/5FU eliminated 71% and 39% of nasopharyngeal carcinoma and normal nasopharyngeal cells, respectively. This study, therefore, showed the strong potential anticancer activity of the novel CF/5-FU formulations, warranting their further investigation.
Identifiants
pubmed: 32801697
doi: 10.2147/IJN.S250047
pii: 250047
pmc: PMC7406330
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Drug Carriers
0
Cellulose
9004-34-6
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5417-5432Informations de copyright
© 2020 Yusefi et al.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Int J Nanomedicine. 2019 Mar 11;14:1633-1657
pubmed: 30880970
J Microencapsul. 2007 May;24(3):274-88
pubmed: 17454438
J Control Release. 2013 Apr 28;167(2):130-7
pubmed: 23391444
J Am Chem Soc. 2005 Feb 2;127(4):1116-7
pubmed: 15669847
Diagnostics (Basel). 2019 Dec 23;10(1):
pubmed: 31877940
Gastroenterology. 2004 Sep;127(3):706-13
pubmed: 15362025
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Int J Pharm. 2015 Mar 1;480(1-2):37-47
pubmed: 25595570
Drug Deliv. 2019 Dec;26(1):318-327
pubmed: 30896267
Int J Cancer. 2008 May 1;122(9):2169-71
pubmed: 18196576
Proc Natl Acad Sci U S A. 1989 Dec;86(23):9524-8
pubmed: 2556716
Int J Nanomedicine. 2017 Mar 14;12:2021-2031
pubmed: 28352172
Carbohydr Polym. 2013 Jun 5;95(1):32-40
pubmed: 23618236
Bioresour Technol. 2009 Sep;100(18):4164-70
pubmed: 19409774
Int J Pharm. 2013 Jan 30;441(1-2):721-7
pubmed: 23089579
Oncologist. 2017 Jan;22(1):107-114
pubmed: 27821793
Food Chem. 2017 Apr 15;221:153-160
pubmed: 27979125
Heliyon. 2019 Sep 03;5(9):e02404
pubmed: 31517126
Gan No Rinsho. 1989 Oct;35(13):1512-6
pubmed: 2585724
J Agric Food Chem. 2011 Mar 9;59(5):1962-7
pubmed: 21288023
Carbohydr Polym. 2017 May 1;163:261-269
pubmed: 28267505
J Clin Oncol. 2012 Feb 20;30(6):608-15
pubmed: 22253466
Int J Cancer. 2009 Oct 15;125(8):1884-93
pubmed: 19588483
Mater Sci Eng C Mater Biol Appl. 2019 Nov;104:109899
pubmed: 31499959
Biomolecules. 2019 Oct 17;9(10):
pubmed: 31627453
Bioresour Technol. 2009 Sep;100(17):3941-7
pubmed: 19359164
Carbohydr Polym. 2016 Oct 5;150:216-26
pubmed: 27312632
Drug Discov Today. 2017 Aug;22(8):1224-1232
pubmed: 28545838
Onco Targets Ther. 2018 Nov 02;11:7591-7600
pubmed: 30464507
BMC Cancer. 2019 Jun 25;19(1):629
pubmed: 31238895
Acta Oncol. 1992;31(6):645-51
pubmed: 1281650
Carbohydr Polym. 2018 Feb 1;181:514-527
pubmed: 29254002
Int J Pharm. 2015 Nov 30;495(2):895-902
pubmed: 26410755
Clin Gastroenterol Hepatol. 2004 Aug;2(8):696-703
pubmed: 15290663
Natl J Maxillofac Surg. 2018 Jul-Dec;9(2):160-166
pubmed: 30546230
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Sci Rep. 2016 Mar 29;6:23761
pubmed: 27021221